Last $14.55 USD
Change Today -0.04 / -0.27%
Volume 6.8K
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

mitsubishi tanabe pharma (MTZXF) Snapshot

Open
$14.55
Previous Close
$14.59
Day High
$14.55
Day Low
$14.55
52 Week High
03/11/14 - $15.05
52 Week Low
10/8/13 - $13.50
Market Cap
8.2B
Average Volume 10 Days
2.0K
EPS TTM
--
Shares Outstanding
561.4M
EX-Date
09/26/14
P/E TM
--
Dividend
$40.00
Dividend Yield
2.73%
Current Stock Chart for MITSUBISHI TANABE PHARMA (MTZXF)

Related News

No related news articles were found.

mitsubishi tanabe pharma (MTZXF) Related Businessweek News

No Related Businessweek News Found

mitsubishi tanabe pharma (MTZXF) Details

Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan and internationally. The company offers autoimmune drugs, including Remicade agent for rheumatoid arthritis and Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis; and Simponi agent for rheumatoid arthritis. It also provides drugs for diabetes and kidney diseases, such as Kremezin agent for chronic renal failure; and Tanatril agent for hypertension and diabetic nephropathy with diabetes mellitus, etc. In addition, the company offers drugs for central nervous system diseases comprising Radicut, a cerebral neuroprotectant; Ceredist agent for spinocerebellar degeneration; Depas, an anti-anxiety agent; and Lexapro, an anti-depressant agent. Further, it provides Maintate agent for hypertension, angina pectoris, ventricular extrasystole, chronic heart failure, and atrial fibrillation; Talion agent for allergic disorders; Urso agent for the improvement of hepatic, biliary, and digestive function; Venoglobulin IH, an intravenous human immunoglobulin; Anplag, an anti-platelet agent; and Herbesser, an agent for angina pectoris and hypertension. Additionally, the company offers vaccines, such as TETRABIK, a combined vaccine for diphtheria, pertussis, tetanus, and poliomyelitis; and influenza. It also provides over-the-counter products, including herbal and digestive medicines, as well as oral solutions for tonic and nutritional supplement; and products for the treatment of skin conditions, allergic rhinitis, and recurrent vaginal candidiasis. The company also offers pharmaceutical information and real estate management services; sells generic pharmaceuticals, chemicals, etc.; invests in bio-ventures; and is involved in distribution and warehouse operations. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.

9,065 Employees
Last Reported Date: 06/20/14
Founded in 1678

mitsubishi tanabe pharma (MTZXF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mitsubishi tanabe pharma (MTZXF) Key Developments

Mitsubishi Tanabe Pharma Corporation, Annual General Meeting, Jun 20, 2014

Mitsubishi Tanabe Pharma Corporation, Annual General Meeting, Jun 20, 2014.

Mitsubishi Tanabe Reports Earnings Results for the Year Ended 31 March 2014; Provides Earnings Guidance for the Financial Year 2014-15

Mitsubishi Tanabe reported earnings results for the year ended 31 March 2014. The company reported that its net sales fell by 1.6% to JPY 412.7 billion in the 2013-14 financial year, which ended on 31 March 2014. During the same period, the company's operating income declined by as much as 14.3% to JPY 59.1 billion, although net income was up by 8.4% to JPY 45.4 billion. In its domestic market, the company saw its ethical drug sales decline by 4.2% to JPY 341.7 billion, although its leading product Remicade (infliximab) recorded an increase of 2.8% to JPY 76.3 billion. Meanwhile, the company's overall ethical drug sales overseas fell by 5.8% to JPY 22.0 billion. However, royalty revenues from Novartis (Switzerland) for the multiple sclerosis treatment Gilenya (fingolimod) shot up by 47.4% to JPY 43.4 billion. Meanwhile, operating income suffered owing to the fact that the company's plasma fractionation products were transferred to other companies following the integration of its plasma fractionation operations in October 2012. Looking ahead, the company forecasts that its net sales will decline by 0.9% to JPY 412.7 billion in financial year 2014-15, and that its net income will decline by 10.8% to JPY 40.5 billion.

Mitsubishi Tanabe Pharma Corporation - Shareholder/Analyst Call

Mitsubishi Tanabe Pharma Corporation - Shareholder/Analyst Call

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MTZXF:US $14.55 USD -0.04

MTZXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MTZXF.
View Industry Companies
 

Industry Analysis

MTZXF

Industry Average

Valuation MTZXF Industry Range
Price/Earnings 18.9x
Price/Sales 2.1x
Price/Book 1.1x
Price/Cash Flow 14.9x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MITSUBISHI TANABE PHARMA, please visit www.mt-pharma.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.